Fig. 1 Incidence Rates of NHL subtypes in the USA, 2000–2011, Surveillance, Epidemiology, and End-Results Program (Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat), Version 8.1.5. Surveillance, Epidemiology, and End…
IgM monoclonal gammopathy of any concentration Bone marrow infiltration by small lymphocytes showing plasmacytic differentiation Intertrabecular pattern of bone marrow infiltration Surface IgM+, CD19+, CD20+, CD22+, CD25+. CD27+, FMC7+, CD5±,…
1 No uptake 2 Uptake ≤ mediastinum 3 Uptake > mediastinum but ≤ liver 4 Uptake moderately higher than liver 5 Uptake markedly higher than liver and/or new lesions X New areas of uptake unlikely to…
Fig. 1 The histopathology of PTLD. a Infectious mononucleosis-like “early” PTLD lesion. b Monomorphic PTLD, Burkitt lymphoma type. c Polymorphic PTLD. d Positive EBV in situ hybridization stain in a PTLD…
Site Procedure Gastric MALT lymphoma Stomach • Endoscopic ultrasound • H. pylori status (by IHC)a • FISH or molecular assay for the t(11;18) translocation Non-gastric MALT lymphoma Breast • Mammography…
Clinical Stage Absolute lymphocyte count Lymphocyte doubling time Bone marrow infiltration pattern Treatment response Age Performance status Genetic IGHV mutational status FISH Low risk: del(13q) Intermediate risk: trisomy 12 High…
© Springer International Publishing Switzerland 2015Andrew M. Evens and Kristie A. Blum (eds.)Non-Hodgkin LymphomaCancer Treatment and Research16510.1007/978-3-319-13150-4_14 Allogeneic Hematopoietic Cell Transplantation in Non-Hodgkin’s Lymphomas Ibrahim Aldoss1 and Auayporn Nademanee1 (1) City of Hope National Medical Center,…
T-cell prolymphocytic leukemia T-cell large granular lymphocytic leukemia Chronic lymphoproliferative disorder of NK cell Aggressive NK leukemia Systemic EBV-positive T-cell lymphoproliferative disorder of childhood Hydroa vaccineforme-like lymphoma Adult T-cell leukemia/lymphoma…
Fig. 1 Our approach to MCL treatment Table 1 Frontline regimens in patients ≤70 years Frontline regimen Age (years) ORR (%) PFS/FFS OS R-Hyper-CVAD [16] ≤81 97 3 years 64 % (≤65 3 years 73 %)…
Expected immunophenotype Follicular lymphoma CD19+, CD20+, IgM ± IgD, monotypic sIg+, CD10+, bcl-6+, bcl-2 ±, HGAL, LMO2; associated with CD21+/CD23+ follicular dendritic cell meshworks Lymphoplasmacytic lymphoma CD19+, CD20+, monotypic sIg+, IgM, CD22+,…
